Sumanasuriya S, De Bono J (2018) Treatment of advanced prostate cancer-a review of current therapies and future promise. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a030635

Article  PubMed  PubMed Central  Google Scholar 

Vlachostergios PJ, Niaz MJ, Sun M, Mosallaie SA, Thomas C, Christos PJ et al (2021) Prostate-specific membrane antigen uptake and survival in metastatic castration-resistant prostate cancer. Front Oncol 11:630589

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C et al (2023) FDA approval summary: Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 29(9):1651–1657

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091–1103

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC et al (2021) [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397(10276):797–804

Article  CAS  PubMed  Google Scholar 

Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN et al (2024) (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404(10459):1227–1239

Article  CAS  PubMed  Google Scholar 

Gafita A, Heck MM, Rauscher I, Tauber R, Cala L, Franz C et al (2020) Early prostate-specific antigen changes and clinical outcome after (177)Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. J Nucl Med 61(10):1476–1483

Article  CAS  PubMed  Google Scholar 

Dai YH, Chen PH, Lee DJ, Andrade G, Vallis KA (2025) A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following Prostate-Specific Membrane Antigen radioligand therapy utilising Lutetium-177 and Actinium-225 in metastatic prostate cancer. Eur Urol 87(4):398–408

Article  CAS  PubMed  Google Scholar 

Network NCC. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer: NCCN; 2024 [Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM et al (2024) Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol 25(1):99–107

Article  CAS  PubMed  Google Scholar 

Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S et al (2024) Efficacy and toxicity of [(177)Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. expanded-access program and comparisons with phase 3 VISION data. J Nucl Med 65(11):1740–1744

Article  CAS  PubMed  Google Scholar 

Almuradova E, Seyyar M, Arak H, Tamer F, Kefeli U, Koca S et al (2024) The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study. Int J Cancer 154(4):692–700

Article  CAS  PubMed  Google Scholar 

Kafka M, Horninger A, di Santo G, Virgolini I, Neuwirt H, Unterrainer LM et al (2024) Real-world outcomes and predictive biomarkers for (177)Lutetium prostate-specific membrane antigen ligand treatment in metastatic castration-resistant prostate cancer: a European Association of Urology Young Academic Urologists Prostate Cancer Working Group multi-institutional observational study. Eur Urol Oncol 7(3):421–429

Article  PubMed  Google Scholar 

Moradi Tuchayi A, Yadav S, Jiang F, Kim ST, Saelee RK, Morley A et al (2024) Real-world experience with (177)Lu-PSMA-617 radioligand therapy after Food and Drug Administration approval. J Nucl Med 65(5):735–739

Article  PubMed  PubMed Central  Google Scholar 

Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A (2021) The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: a review of the lessons learnt so far. Nucl Med Biol 98–99:30–39

Article  PubMed  Google Scholar 

Wu S, Hu W, Chen M, Xiao X, Liu R (2024) A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617. Sci Rep 14(1):25712

Article  CAS  PubMed  PubMed Central  Google Scholar